If TuHURA is successful with its deep-seated tumor trial in Merkel cell carcinoma, it could expand IFx-2.0's addressable market by 30%. Join CEO Dr. James Bianco as he explains.
$HURA
#ImmunoOncology #CancerResearch #LifeSciences
youtube.com/shorts/vl5dw...
